… . (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it has been … providing feedback on the results. Eisai identifies “Business activities with consideration … material issues. Based on the “Eisai Network Companies Environmental Protection Policy …

… over 100 employees. MISSISSAUGA — Eisai Limited, a research and development … past 14 years, and Eisai’s expansion deepens our … grow.” With this expansion, Eisai’s Canada site has grown … Tatsuyuki Yasuno, chair and CEO of Eisai Inc., president, Americas Region …

… week. CEO Haruo Naito described on the call Eisai’s … targeting recently diagnosed patients, Eisai wants to boost understanding of … and begins treatment. Overall, Eisai is aiming to increase … s awareness-raising efforts.  Eisai’s earnings presentation included …

… limited by healthcare infrastructure, which Eisai and Biogen suggest have hindered … is too advanced, Biogen CEO Chris Viehbacher said during an … the two key elements that Eisai and Biogen hope could … that ended in March, Eisai recorded 26.1 billion Japanese …

… Corporate Officer and CEO of Eisai, Haruo Naito has … Chief Executive Officer (CEO), Eisai Jun. 2004 - Director, President (Representative Corporate Officer) and CEO, Eisai … Representative Corporate Officer and CEO, Eisai (current) Industry Association …

… 4 billion during the period. Eisai-partnered Leqembi is now into … eligible patients,” according to the CEO. It’s been a “ … between us and donanemab,” the CEO said. “The most important … “desperately need treatment," the CEO said. Zurzuvae, meanwhile, has so …

… Christopher Viehbacher, president and chief executive officer at Biogen, said: … years.” Haruo Naito, Eisai’s chief executive officer, added that the … as soon as possible”. Eisai serves as the lead … promoting the product and Eisai having final decision-making …

The European Commission (EC) on Tuesday approved Eisai Co., Ltd. ESALY and Biogen Inc.’s BIIB amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab), The Commission said it granted the approval under strict conditions. Lecanemab is indicated for adult …

… decreasing amyloid-beta plaques. Eisai is spearheading the development … with both Biogen and Eisai responsible for the joint … commercialisation of the product. Eisai holds final decision-making … Eisai distributing the product as the holder of the MA. Biogen CEO …

Several pharma CEOs met with Chinese President Xi … 1. AstraZeneca, Sanofi, Lilly, Pfizer CEOs meet with Xi Jinping amid … US-China trade tensions The CEOs of AstraZeneca, Bayer, Boehringer … LaunXP in $60M deal 8. Eisai offloads proton pump inhibitor Chinese …